Immunotherapy in adult acute lymphoblastic leukemia: current therapeutic landscape
Adult acute lymphoblastic leukemia (ALL) is undergoing a major transformation, driven by the integration of monoclonal antibodies, bispecific T‑cell engagers, and chimeric antigen receptor (CAR) T‑cell therapies into treatment algorithms. This short review summarizes current evidence for the frontline management of...